Partnership provides access to Certara’s industry-standard Phoenix™ Platform to advance drug development in China
PRINCETON, N.J.—Mar 1 , 2021. Certara, a global leader in biosimulation, today announced that it has renewed Peking Union Medical College Hospital (PUMCH) as an academic Center of Excellence for model-informed drug development. Through this partnership, Certara will provide training and access to its leading Phoenix™ Platform for biosimulation to PUMCH’s faculty, students, and researchers. The Phoenix Platform is the biopharmaceutical industry’s industry-standard software for managing, analyzing, and reporting pharmacokinetic, pharmacodynamic, and toxicokinetic data.
“We are thrilled to announce this partnership with PUMCH, one of the most prestigious academic institutions in China,” said Thomas Kerbusch, Ph.D., chief growth officer at Certara and executive director of at Certara Shanghai Pharmaceutical Consultation. “We recognize China’s biopharmaceutical landscape is rapidly evolving with an increasing adoption of biosimulation, and many highly innovative companies seek global approval of their products. Together with PUMCH, we look forward to fostering innovation in China through biosimulation.”
The Center of Excellence program enhances research and training in biosimulation, with a particular focus on pharmacometrics. In addition, Certara is providing faculty, students, and researchers with nearly 100 Phoenix software user licenses of Phoenix WinNonlin™, Phoenix NLME™, and In Vitro-In Vivo Correlation Toolkit™ Software, to support coursework, academic research, and collaboration on projects with Certara. PUMCH provides training on Phoenix software in student courses. PUMCH has also licensed Certara’s Simcyp™ PBPK Simulator since 2012.
Certara has eight additional academic Centers of Excellence worldwide. For more information, please visit: https://www.certara.com/company/partners/academic-centers-of-excellence/.
Certara accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Chief Strategy and Marketing Officer